APOE and atherosclerosis: GP-17 treatment (50 mg/kg) significantly decreased blood lipid levels, increased the expression of antioxidant enzymes, and decreased atherosclerotic lesion size, thus effectively preventing the progression of atherosclerosis in ApoE-/- mice.